Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease

Clinica Chimica Acta

Volumn 420, Issue , 2013, Pages 69-75

  Chang, Chiz Tzung ^a   Liao, Hsin Yi ^a   Chang, Chia Ming ^a   Chen, Chia Ying ^a   Chen, Chu Huang ^a,b,c,d   Yang, Chao Yuh ^a,b,c,d   Tsai, Fuu Jen ^a   Chen, Chao Jung ^a,e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS HEART INSTITUTE   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atherosclerotic vascular disease; Glycation; Gradient gel; HDL; Mass spectrometry; Oxidation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC VASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OXIDATION KINETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ADULT; APOLIPOPROTEIN C-I; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLYCOSYLATION; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VASCULAR DISEASES;

EID: 84877596414     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.10.017     Document Type: Article

References (50)

1. Mitra S., Goyal T., Mehta J.L. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011, 25:419-429.
2. Humphries S.E., Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004, 3:227-235.
3. Brooks E.L., Preis S.R., Hwang S.J., Morabito J.M., Benjamin E.J., Kelly-Hayes M., et al. Health insurance and cardiovascular disease risk factors. Am J Med 2010, 123:741-747.
4. Sarnak M.J., Levey A.S. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis 2000, 10:169-180.
5. Vogel R.A., Benitez R.M. Noninvasive assessment of cardiovascular risk: from Framingham to the future. Rev Cardiovasc Med 2000, 1:34-42.
6. Higashiyama A, Wakabayashi I, Kubota Y, Adachi Y, Hayashibe A, Nishimura K, et al. Does high-sensitivity C-reactive protein or low-density lipoprotein cholesterol show a stronger relationship with the cardio-ankle vascular index in healthy community dwellers?: the KOBE Study. J Atheroscler Thromb in press.
7. Yeboah J., McClelland R.L., Polonsky T.S., Burke G.L., Sibley C.T., O'Leary D., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012, 308:788-795.
8. Greenland P., Alpert J.S., Beller G.A., Benjamin E.J., Budoff M.J., Fayad Z.A., et al. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122(2010):e584-e636.
9. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
10. Kontush A., Chantepie S., Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881-1888.
11. Terasaka N., Wang N., Yvan-Charvet L., Tall A.R. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. PNAS 2007, 104:15093-15098.
12. Farmer J.A., Liao J. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep 2011, 13:107-114.
13. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., Fuster V., Goldstein J., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919.
14. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEJM 2011, 364:127-135.
15. Calabresi L., Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med 2010, 20:50-53.
16. Frank P.G., Marcel Y.L. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000, 41:853-872.
17. Liu M., Subbaiah P.V. Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E. Biochim Biophys Acta 1993, 1168:144-152.
18. Dautin G., Soltani Z., Ducloux D., Gautier T., Paris de Barros J.P., Gambert P., et al. Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int 2007, 72:871-878.
19. Jones M.K., Catte A., Li L., Segrest J.P. Dynamics of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I. Biochemistry 2009, 48:11196-11210.
20. Shao B., Cavigiolio G., Brot N., Oda M.N., Heinecke J.W. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. PNAS 2008, 105:12224-12229.
21. Westerterp M., Van Eck M., de Haan W., Offerman E.H., Van Berkel T.J., Havekes L.M., et al. Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages. Atherosclerosis 2007, 195:e9-e16.
22. Moore D., McNeal C., Macfarlane R. Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease. Biochem Biophys Res Commun 2010, 404:1034-1038.
23. Gordon S.M., Davidson W.S. Apolipoprotein A-I mimetics and high-density lipoprotein function. Curr Opin Endocrinol Diabetes Obes 2012, 19:109-114.
24. Patel J.V., Abraheem A., Creamer J., Gunning M., Hughes E.A., Lip G.Y. Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. Eur J Heart Fail 2010, 12:254-259.
25. Hoang A., Murphy A.J., Coughlan M.T., Thomas M.C., Forbes J.M., ÒBrien R., et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic propertie. Diabetologia 2007, 50:1770-1779.
26. Vaisar T., Mayer P., Nilsson E., Zhao X.Q., Knopp R., Prazen B.J. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010, 411:972-979.
27. Brock J.W., Jenkins A.J., Lyons T.J., Klein R.L., Yim E., Lopes-Virella M., et al. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008, 49:847-855.
28. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Birkeland K.I., et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005, 25:815-820.
29. Lapolla A., Brioschi M., Banfi C., Tremoli E., Bonfante L., Cristone S., et al. On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients. J Mass Spectrom 2008, 43:74-81.
30. S.B. Nair, R. Malik, R.S. Khattar, Carotid intima-media thickness: ultrasound measurement, prognostic value and role in clinical practice. Postgrad Med J in press.
31. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1995, 134:1345-1353.
32. Bondarenko P.V., Cockrill S.L., Watkins L.K., Cruzado I.D., Macfarlane R.D. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J Lipid Res 1999, 40:543-555.
33. Conde-Knape K., Bensadoun A., Sobel J.H., Cohn J.S., Shachter N.S. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res 2002, 43:2136-2145.
34. Berbee J.F., van der Hoogt C.C., Sundararaman D., Havekes L.M., Rensen P.C. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 2005, 46:297-306.
35. Poensgen J. Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes. Biochim Biophys Acta 1990, 1042:188-192.
36. Allard L., Lescuyer P., Burgess J., Leung K.Y., Ward M., Walter N., et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004, 4:2242-2251.
37. Wroblewski M.S., Wilson-Grady J.T., Martinez M.B., Kasthuri M.T., McMillan K.R., Flood-Urdangarin C., et al. A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J 2006, 273:4707-4715.
38. Rader D.J. Illuminating HDL-is it still a viable therapeutic target?. NEJM 2007, 357:2180-2183.
39. Shao B., Oda M.N., Bergt C., Fu X., Green P.S., Brot N., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 2006, 281:9001-9004.
40. Liu D., Ji L., Zhang D., Tong X., Pan B., Liu P., et al. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diabetes Metab Res Rev 2012, 28:186-195.
41. Nobecourt E., Davies M.J., Brown B.E., Curtiss L.K., Bonnet D.J., Charlton F., et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007, 50:643-653.
42. Haraba R., Suica V.I., Uyy E., Ivan L., Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 2011, 346:361-368.
43. Matsunaga T., Iguchi K., Nakajima T., Koyama I., Miyazaki T., Inoue I., et al. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem Biophys Res Commun 2001, 287:714-720.
44. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000, 43:312-320.
45. Jin S., Cho K.H. Water extracts of cinnamon and clove exhibits potent inhibition of protein glycation and anti-atherosclerotic activity in vitro and in vivo hypolipidemic activity in zebrafish. Food Chem Toxicol 2011, 49:1521-1529.
46. Calvo C., Talussot C., Ponsin G., Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988, 153:1060-1067.
47. Machado A.P., Pinto R.R., Moyses Z.P., Nakandakare E.R., Quintao E.C., Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol 2006, 38:392-403.
48. Calvo C., Verdugo C. Association in vivo of glycated apolipoprotein A-I with high density lipoproteins. Eur J Clin Chem Clin Biochem 1992, 30:3-5.
49. Nobecourt E., Tabet F., Lambert G., Puranik R., Bao S., Yan L., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30:766-772.
50. Brace R.J., Sorrenson B., Sviridov D., McCormick S.P. A gel-based method for purification of apolipoprotein A-I from small volumes of plasma. J Lipid Res 2010, 51:3370-3376.